American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...

Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...

Tariffs targeted at countries — reciprocal or regular — will likely be paid by multinational companies, dampening the outlook ...

Discover how the obesity drug market is set to hit $173.5 billion by 2031, reshaping obesity and cardiometabolic treatments.

Ancient DNA is telling us more and more about humans and environments long past. Could it also help rescue the future?

This summary covers recent health news, including stable pig prices in Germany, investor focus on AstraZeneca's China probe, and the withdrawal of Argentina from WHO after Trump's exit. Additionally, ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo Nordisk's strong earnings were countered by losses in technology stocks.

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...